Latest News
Conference Coverage
Ixekizumab psoriasis outcomes, sliced and diced
WAIKOLOA, HAWAII – The jaw-dropping NNT to achieve complete skin clearance: 2.6 patients.
News
AAD, NPF release two joint guidelines on treatment, management of psoriasis
The next guidelines will address phototherapy, topical therapy, nonbiologic systemic medications, and treatment of pediatric patients.
Latest News
TNF inhibitor prices rose despite increased drug class competition
Estimated treatments costs for etanercept, infliximab, and adalimumab would have been 40%-45% lower without new competition, a new analysis finds...
Conference Coverage
What’s new with adalimumab? Plenty
WAIKOLOA, HAWAII – New information includes reassuring new long-term, real-world safety data, plus a simple early predictor of PASI 75 response....
News
Biologics curb coronary artery plaques in severe psoriasis
Treating psoriasis with biologics improves coronary plaque profiles, suggesting an impact on inflammation and opportunity to reduce cardiovascular...
News
Different disease features found with family history of psoriasis versus PsA
The finding suggests different genetic backgrounds and pathogenic mechanisms in these subsets.
Conference Coverage
Guselkumab tops secukinumab over 48 weeks for plaque psoriasis
CAYMAN ISLANDS – In both groups, the PASI 90 increased similarly in the first month, but was consistently higher in the guselkumab group at week...
Conference Coverage
Comorbidities may cut effectiveness of psoriasis biologics
PARIS – In the PSO-BIO-REAL study, PASI 100 rate dropped as the number of comorbidities rose.
Conference Coverage
Brodalumab raced past ustekinumab to PASI 100
PARIS – Pooled analysis of phase 3 trials spotlights one clinical setting where brodalumab is particularly advantageous.
News
Chronic infections such as HCV, HIV, and TB cause unique problems for psoriasis patients